Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ruijin Hospital | OTHER |
| Nanfang Hospital, Southern Medical University | OTHER |
| Zhejiang University | OTHER |
Not provided
Not provided
Not provided
Not provided
This observational study aims to emulate a hypothetical pragmatic, multicenter, non-blinded clinical trial enrolling adult patients undergoing haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with grafts derived from either cousin or sibiling donors.
The main research question is whether cousin donor-derived haplo-HSCT is associated with inferior clinical outcomes relative to sibling donor-derived haplo-HSCT.
Study participants consist of adult patients diagnosed with hematological malignancies who underwent cousin or sibiling haplo-HSCT between 2017 and 2024, and all eligible recipients will receive regular follow-up assessments.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cousin haplo-HSCT | Patients who underwent haploidentical hematopoietic stem cell transplantation with cousin donors. Grouping was based on donor age recorded in retrospective clinical data. | ||
| Sibling haplo-HSCT | Patients who underwent haploidentical hematopoietic stem cell transplantation with sibling donors. Grouping was based on donor age recorded in retrospective clinical data. |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Overall survival | estimated overall survival at 2 year | 2 years after transplantation |
| Graft-versus-host disease-free and relapse-free survival | estimated graft-versus-host disease-free and relapse-free survival at 2 year | 2 years after transplantation |
| Cumulative incidence of acute graft-versus-host disease | estimated cumulative incidence of acute graft-versus-host disease at 180 day | 180 days after transplantation |
| Cumulative incidence of chronic graft-versus-host disease | estimated cumulative incidence of chronic graft-versus-host disease at 2 year | 2 years after transplantation |
| Measure | Description | Time Frame |
|---|---|---|
| Cumulative incidence of relapse | estimated cumulative incidence of relapse at 2 year | 2 years after transplantation |
| Non-relapse mortality | estimated non-relapse mortality at 2 year |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
This multicenter, retrospective observational study included adult patients with hematological malignancies undergoing their first haploidentical hematopoietic stem cell transplantation at four clinical centers between 2017 to 2024. Eligible patients were identified through retrospective clinical records and stratified by donor kinship recorded at transplant, classified as either cousin or sibling donor graft recipients.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Yang Xu | The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| The First Affiliated Hospital of Soochow University | Suzhou | Jiangsu | 215000 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D019337 | Hematologic Neoplasms |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D006402 | Hematologic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
| 2 years after transplantation |
| Cumulative incidence of grade III-IV acute graft-versus-host disease | estimated cumulative incidence of grade III-IV acute graft-versus-host disease at 180 day | 180 days after transplantation |
| Cumulative incidence of extensive chronic graft-versus-host disease | estimated cumulative incidence of extensive chronic graft-versus-host disease at 2 year | 2 years after transplantation |